Beginning in April 2023, there have been reports of Syfovre eye injury cases, including retinal vasculitis resulting in significant vision loss. As of the beginning of April 2024, however, retina specialists seem to agree that both the etiology and the incidence rate of retinal vasculitis after Syfovre injections remain uncertain. Put in more … [Read more...]
The U.S. banned asbestos, but its health impact will still be felt for decades
A new rule announced by the Environmental Protection Agency this week puts an end to the use of asbestos, a known carcinogen, in the United States. But researchers caution that we’ll likely still be dealing with the mineral’s public health harms for decades. The recently announced ban covers all forms of asbestos, including chrysotile asbestos, … [Read more...]
US Bans Sole Type of Asbestos, Parts Industries Still Import
The US will ban the only type of raw asbestos fiber known to be imported to the country [(chrysotile asbestos)] as part of a broader rule that also will ban all known uses of the cancer-causing mineral and imported equipment made with it, top EPA and White House officials announced on Monday. Many people are shocked to learn asbestos isn’t … [Read more...]
Impact of Surgery on Disease Progression and Survival of Patients with Pleural Mesothelioma
BACKGROUND: The effects of surgery on the survival of patients with pleural mesothelioma remain poorly understood. We compared the therapeutic outcomes of patients receiving neoadjuvant chemotherapy followed by surgery or refusing surgery for pleural mesothelioma. METHODS: This retrospective study included consecutive patients who were … [Read more...]
Syfovre Eye Injuries Decreased Vision For Patients After Syfovre Treatments
Members of the American Society of Retina Specialists (ASRS) Research and Safety in Therapeutics (ReST) Committee recently issued a general report on cases where Syfovre eye injuries decreased vision for patients after Syfovre treatments. In summary, this report revealed that at least 13 patients had Syfovre retinal-related vision loss in … [Read more...]
2024 BIA-ALCL Report by the American Association of Plastic Surgeons
In March 2017 we wrote this article, "Breast Implants Linked to Rare Lymphoma Blood Cancer", which started our coverage of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) related to textured breast implants. Seven years later, we point out an article published on February 27, 2024, by the Plastic and Reconstructive Surgery … [Read more...]
Wegovy / Rybelsus / Ozempic DVT Blood Clots Side Effects Cases
Wegovy, Rybelsus, and Ozempic DVT blood clots side effects have not received as much attention as adverse event reports that involve severe stomach conditions such as gastroparesis, gastric stasis, and stomach paralysis. Ozempic, Wegovy, and Rybelsus are three popular GLP-1 receptor agonists containing semaglutide that are increasingly used as … [Read more...]
Pegargiminase Confers Survival Benefit in Nonepithelioid Pleural Mesothelioma
Adding [ new treatment drug ] pegargiminase to standard chemotherapy can improve outcomes in patients with chemotherapy-naïve, nonepithelioid pleural mesothelioma, according to research published in JAMA Oncology. [Szlosarek PW, Creelan BC, Sarkodie T, et al. Pegargiminase plus first-line chemotherapy in patients with nonepithelioid pleural … [Read more...]
Gastroparesis Cases Involving Ozempic, Rybelsus, Wegovy, and Trulicity as Weight-loss Drugs
We are handling gastroparesis cases involving Ozempic, Rybelsus, Wegovy, and Trulicity as drug injury lawsuits filed against the responsible pharmaceutical companies. In this piece, we point out two medical journal articles that present a few gastroparesis cases involving the use of semaglutide (Ozempic, Rybelsus, Wegovy) or dulaglutide … [Read more...]
FDA Fast Tracks UV1, Ipilimumab, and Nivolumab in Malignant Mesothelioma
The FDA has granted a fast track designation to the combination of UV1 with ipilimumab and nivolumab for the treatment of patients with unresectable malignant pleural mesothelioma. This regulatory decision is supported by findings from the phase 2 NIPU trial which is evaluating UV1 in patients with unresectable malignant pleural mesothelioma. … [Read more...]
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 22
- Next Page »